Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 120

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 120
---
 -II Clinical Trials. As part of our efforts, in November 2024 we entered into a     
 Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID), a component of the   
 NIH under the U.S. Department of Health and Human Services (HHS), for non-clinical and pre-clinical services funded by the Division   
 of Microbiology and Infectious Diseases                                                                                               |

| ● | Implement strategy to minimize time to realization of the Nano Mupirocin, including: |

| - | forging strategic alliances                                                                                                              
 with established pharmaceutical companies and pursuing non-dilutive funding through governmental and non-governmental grant programs,    
 early in the development process, especially Phase 1-2 clinical trials.  These partnerships could range from non-profit organizations    
 like Carb-X for advancing novel treatment development to co-development with larger Pharma companies. However, there can be no assurance 
 that such funding will be awarded or sufficient to support our development plan;                                                         |

| - | Concentrating on indications                                                                                                               
 where antibiotic resistance poses a significant and immediate clinical challenge, and where Nano-Mupirocin can offer a distinct advantage; |
| - 
 - | Accelerating regulatory approvals through                                                                                                  
 pathways like Breakthrough Therapy Designation or Priority Review;                                                                         
 Utilizing adaptive regulatory pathways                                                                                                     
 and engaging in early dialogue with regulatory agencies to expedite the development timeline in order to achieve early regulatory          
 milestones;                                                                                                                                |
| - | To further develop and                                                                                                                     
 strengthen its IP strategy and submit more patent applications for methods of production and methods of use, including Orphan Drug         
 Designation protection for chosen disease.;                                                                                                |

| ● | To generate high-impact publications in reputable scientific and medical journals in collaboration with KOLs and leading researchers. |

| ● | If we successfully conduct                                                                                                       
 clinical trials, we plan to publish pivotal trials data and to present at major pharmaceutical and medical industry conferences. 
 Positive data can significantly increase valuation and attract acquisition interest.                                             |

Our strategy for maximizing long-term value includes:

| ● | Expanding the development program to include a wider range of indications, demonstrating the versatility and broad applicability of Nano-Mupirocin across various infectious diseases. This can significantly enhance the long-term market potential. |

| ● | Developing a comprehensive target market strategy that includes key regions affected by antibiotic resistance. Tailoring market approaches to fit regional healthcare landscapes is expected to maximize adoption and revenue generation. |

| ●